335 related articles for article (PubMed ID: 31128948)
1. Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer.
Koole SN; Kieffer JM; K Sikorska ; Schagen van Leeuwen JH; Schreuder HWR; Hermans RH; de Hingh IH; van der Velden J; Arts HJ; van Ham MAPC; Aalbers AG; Verwaal VJ; Van de Vijver KK; Sonke GS; van Driel WJ; Aaronson NK
Eur J Surg Oncol; 2021 Jan; 47(1):101-107. PubMed ID: 31128948
[TBL] [Abstract][Full Text] [Related]
2. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.
Koole S; van Stein R; Sikorska K; Barton D; Perrin L; Brennan D; Zivanovic O; Mosgaard BJ; Fagotti A; Colombo PE; Sonke G; Driel WJV;
Int J Gynecol Cancer; 2020 Jun; 30(6):888-892. PubMed ID: 32205449
[TBL] [Abstract][Full Text] [Related]
3. Central radiology assessment of the randomized phase III open-label OVHIPEC-1 trial in ovarian cancer.
Koole SN; Bruijs L; Fabris C; Sikorska K; Engbersen M; Schagen van Leeuwen JH; Schreuder HWR; Hermans RH; van der Velden J; Arts HJG; van Ham M; Van Dam P; Vuylsteke P; Lahaye M; Sonke G; Driel WV
Int J Gynecol Cancer; 2020 Dec; 30(12):1928-1934. PubMed ID: 33046576
[TBL] [Abstract][Full Text] [Related]
4. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
van Driel WJ; Koole SN; Sikorska K; Schagen van Leeuwen JH; Schreuder HWR; Hermans RHM; de Hingh IHJT; van der Velden J; Arts HJ; Massuger LFAG; Aalbers AGJ; Verwaal VJ; Kieffer JM; Van de Vijver KK; van Tinteren H; Aaronson NK; Sonke GS
N Engl J Med; 2018 Jan; 378(3):230-240. PubMed ID: 29342393
[TBL] [Abstract][Full Text] [Related]
5. Rationale and study design of the CHIPPI-1808 trial: a phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer patients treated with primary or interval cytoreductive surgery.
El Hajj H; Vanseymortier M; Hudry D; Bogart E; Abdeddaim C; Leblanc E; Le Deley MC; Narducci F
ESMO Open; 2021 Apr; 6(2):100098. PubMed ID: 33819750
[TBL] [Abstract][Full Text] [Related]
6. Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
Munoz-Zuluaga CA; Sardi A; Sittig M; Gushchin V; King MC; Nieroda C; Lopez-Ramirez F; Diaz-Montes TP
Int J Surg Oncol; 2020; 2020():1467403. PubMed ID: 33381312
[TBL] [Abstract][Full Text] [Related]
7. A novel treatment protocol with 6 cycles of neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in stage III primary ovarian cancer.
Marrelli D; Petrioli R; Cassetti D; D'Ignazio A; Marsili S; Mazzei MA; Lazzi S; Roviello F
Surg Oncol; 2021 Jun; 37():101523. PubMed ID: 33545658
[TBL] [Abstract][Full Text] [Related]
8. Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial.
Koole SN; van Lieshout C; van Driel WJ; van Schagen E; Sikorska K; Kieffer JM; Schagen van Leeuwen JH; Schreuder HWR; Hermans RH; de Hingh IH; van der Velden J; Arts HJ; Massuger LFAG; Aalbers AG; Verwaal VJ; Van de Vijver KK; Aaronson NK; van Tinteren H; Sonke GS; van Harten WH; Retèl VP
J Clin Oncol; 2019 Aug; 37(23):2041-2050. PubMed ID: 31251694
[TBL] [Abstract][Full Text] [Related]
9. Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC/IVA epithelial ovarian cancer.
Sinukumar S; Damodaran D; Ray M; Mehta S; Paul L; Bhatt A
Eur J Surg Oncol; 2021 Jun; 47(6):1427-1433. PubMed ID: 33509612
[TBL] [Abstract][Full Text] [Related]
10. Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Chambers LM; Yao M; Morton M; Gruner M; Chichura A; Horowitz M; Costales AB; Rose PG; Michener CM; Debernardo R
Gynecol Oncol; 2021 May; 161(2):389-395. PubMed ID: 33551202
[TBL] [Abstract][Full Text] [Related]
11. Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial.
Lim MC; Chang SJ; Park B; Yoo HJ; Yoo CW; Nam BH; Park SY;
JAMA Surg; 2022 May; 157(5):374-383. PubMed ID: 35262624
[TBL] [Abstract][Full Text] [Related]
12. Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer.
Costales AB; Chambers L; Chichura A; Rose PG; Mahdi H; Michener CM; Yao M; Debernardo R
J Gynecol Obstet Hum Reprod; 2021 May; 50(5):101844. PubMed ID: 32590110
[TBL] [Abstract][Full Text] [Related]
13. Quality of life in a phase 2 trial of short-course hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking surgery for high tumor burden ovarian cancer.
Lustosa RJC; Batista TP; Carneiro VCG; Badiglian-Filho L; Costa RLR; Lopes A; Sarmento BJQ; Lima JTO; Mello MJG; LeÃo CS
Rev Col Bras Cir; 2020; 47():e20202534. PubMed ID: 32667582
[TBL] [Abstract][Full Text] [Related]
14. Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy Improves Survival with Acceptable Safety for Advanced Ovarian Cancer: A Clinical Study of 100 Patients.
Zhang J; Li XB; Ji ZH; Ma R; Bai WP; Li Y
Biomed Res Int; 2021; 2021():5533134. PubMed ID: 34258265
[TBL] [Abstract][Full Text] [Related]
15. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.
Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M
Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829
[TBL] [Abstract][Full Text] [Related]
16. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study.
Spiliotis J; Halkia E; Lianos E; Kalantzi N; Grivas A; Efstathiou E; Giassas S
Ann Surg Oncol; 2015 May; 22(5):1570-5. PubMed ID: 25391263
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis: a prospective cohort study.
Yu P; Ye Z; Dai G; Zhang Y; Huang L; Du Y; Cheng X
BMC Cancer; 2020 Nov; 20(1):1108. PubMed ID: 33198674
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer.
Lei Z; Wang Y; Wang J; Wang K; Tian J; Zhao Y; Chen L; Wang J; Luo J; Jia M; Tang H; He Q; Liao Q; Yang X; Guan T; Wang L; Cui S;
JAMA Netw Open; 2020 Aug; 3(8):e2013940. PubMed ID: 32840622
[TBL] [Abstract][Full Text] [Related]
19. Morbidity after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with carboplatin used for ovarian, tubal, and primary peritoneal cancer.
Mikkelsen MS; Christiansen T; Petersen LK; Blaakaer J; Iversen LH
J Surg Oncol; 2019 Sep; 120(3):550-557. PubMed ID: 31267569
[TBL] [Abstract][Full Text] [Related]
20. Hyperthermic intraperitoneal chemotherapy in interval debulking surgery for advanced epithelial ovarian cancer: A single-center, real-life experience.
Ghirardi V; Ronsini C; Trozzi R; Di Ilio C; Di Giorgio A; Cianci S; Draisci G; Scambia G; Fagotti A
Cancer; 2020 Dec; 126(24):5256-5262. PubMed ID: 32931024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
